Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Anna Lundgren

Showing results (51-60 of 63) with videos related to

Pageof 7
Sort By:
Clinical and Vaccine Immunology : CVI|August 20, 2011
Refinement of a human challenge model for evaluation of enterotoxigenic Escherichia coli vaccinesClayton Harro, Subhra Chakraborty, Andrea Feller, et al.
Chemosphere|November 20, 2024
The T cell response to SARS-CoV-2 mRNA vaccine in adults with high exposure to perfluoroalkyl substances from Ronneby, SwedenAxel G Andersson, Anna Lundgren, Yiyi Xu, et al.
Infection and Immunity|December 25, 2004
Mucosal FOXP3-expressing CD4+ CD25high regulatory T cells in Helicobacter pylori-infected patientsAnna Lundgren, Erika Strömberg, Asa Sjöling, et al.
Clinical and Experimental Immunology|April 18, 2023
Plasmablasts in previously immunologically naïve COVID-19 patients express markers indicating mucosal homing and secrete antibodies cross-reacting with SARS-CoV-2 variants and other beta-coronavirusesAnna Lundgren, Susannah Leach, Hannes Axelsson, et al.
Plos One|October 4, 2021
Correction: Serum-IgG responses to SARS-CoV-2 after mild and severe COVID-19 infection and analysis of IgG non-respondersEmelie Marklund, Susannah Leach, Hannes Axelsson, et al.
Plos One|October 21, 2020
Serum-IgG responses to SARS-CoV-2 after mild and severe COVID-19 infection and analysis of IgG non-respondersEmelie Marklund, Susannah Leach, Hannes Axelsson, et al.
Environmental Health Perspectives|August 14, 2023
High Exposure to Perfluoroalkyl Substances and Antibody Responses to SARS-CoV-2 mRNA Vaccine-an Observational Study in Adults from Ronneby, SwedenAxel G Andersson, Anna Lundgren, Yiyi Xu, et al.
Plos Pathogens|September 20, 2008
Interleukin-17A mediates acquired immunity to pneumococcal colonizationYing-Jie Lu, Jane Gross, Debby Bogaert, et al.
JCI Insight|November 29, 2022
Longitudinal single-cell analysis of SARS-CoV-2-reactive B cells uncovers persistence of early-formed, antigen-specific clonesLydia Scharf, Hannes Axelsson, Aikaterini Emmanouilidi, et al.
Journal of Travel Medicine|April 26, 2023
Safety and immunogenicity of ETVAX®, an oral inactivated vaccine against enterotoxigenic Escherichia coli diarrhoea: a double-blinded, randomized, placebo-controlled trial amongst Finnish travellers to Benin, West AfricaAnu Kantele, Marianna Riekkinen, T Sakari Jokiranta, et al.
Pageof 7

Showing results (51-60 of 63) with videos related to

Sort By:
Pageof 7
Clinical and Vaccine Immunology : CVI|August 20, 2011
Refinement of a human challenge model for evaluation of enterotoxigenic Escherichia coli vaccinesClayton Harro, Subhra Chakraborty, Andrea Feller, et al.
Chemosphere|November 20, 2024
The T cell response to SARS-CoV-2 mRNA vaccine in adults with high exposure to perfluoroalkyl substances from Ronneby, SwedenAxel G Andersson, Anna Lundgren, Yiyi Xu, et al.
Infection and Immunity|December 25, 2004
Mucosal FOXP3-expressing CD4+ CD25high regulatory T cells in Helicobacter pylori-infected patientsAnna Lundgren, Erika Strömberg, Asa Sjöling, et al.
Clinical and Experimental Immunology|April 18, 2023
Plasmablasts in previously immunologically naïve COVID-19 patients express markers indicating mucosal homing and secrete antibodies cross-reacting with SARS-CoV-2 variants and other beta-coronavirusesAnna Lundgren, Susannah Leach, Hannes Axelsson, et al.
Plos One|October 4, 2021
Correction: Serum-IgG responses to SARS-CoV-2 after mild and severe COVID-19 infection and analysis of IgG non-respondersEmelie Marklund, Susannah Leach, Hannes Axelsson, et al.
Plos One|October 21, 2020
Serum-IgG responses to SARS-CoV-2 after mild and severe COVID-19 infection and analysis of IgG non-respondersEmelie Marklund, Susannah Leach, Hannes Axelsson, et al.
Environmental Health Perspectives|August 14, 2023
High Exposure to Perfluoroalkyl Substances and Antibody Responses to SARS-CoV-2 mRNA Vaccine-an Observational Study in Adults from Ronneby, SwedenAxel G Andersson, Anna Lundgren, Yiyi Xu, et al.
Plos Pathogens|September 20, 2008
Interleukin-17A mediates acquired immunity to pneumococcal colonizationYing-Jie Lu, Jane Gross, Debby Bogaert, et al.
JCI Insight|November 29, 2022
Longitudinal single-cell analysis of SARS-CoV-2-reactive B cells uncovers persistence of early-formed, antigen-specific clonesLydia Scharf, Hannes Axelsson, Aikaterini Emmanouilidi, et al.
Journal of Travel Medicine|April 26, 2023
Safety and immunogenicity of ETVAX®, an oral inactivated vaccine against enterotoxigenic Escherichia coli diarrhoea: a double-blinded, randomized, placebo-controlled trial amongst Finnish travellers to Benin, West AfricaAnu Kantele, Marianna Riekkinen, T Sakari Jokiranta, et al.
Pageof 7